

**Form 51-102F3**  
**Material Change Report**

**Item 1**                    **Name and Address of Company**

**XTACY THERAPEUTICS CORP.** (the “Company”)  
1100 – 1111 Melville Street  
Vancouver, BC V6E 3V6

**Item 2 -**            **Date of Material Change**

October 8, 2024

**Item 3**            **News Release**

A news release was issued and disseminated on October 8, 2024, and filed on SEDAR+ ([www.sedarplus.ca](http://www.sedarplus.ca)). and with the CSE.

**Item 4**            **Summary of Material Change**

The Company announced the resignation of Ms. Ashleigh Vogstad from the Board of Directors and further announced the appointment of Mr. Vanni Barbon to serve as a member of the Board.

**Item 5**            **Full Description of Material Change**

See the News Release attached as Schedule “A”.

**Item 6**            **Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7**            **Omitted Information**

Not applicable.

**Item 8**            **Executive Officer**

The following senior officer of the Company is knowledgeable about the material change and this report:

Meris Kott, CEO and Director  
Email: [info@xtacytherapeutics.com](mailto:info@xtacytherapeutics.com)  
Phone: 604-484-0355

**Item 9**            **Date of Report**

October 8, 2024

SCHEDULE "A"



**XTACY Therapeutics Corporate Update**

**Vancouver: October 8, 2024 – Xtacy Therapeutics Corp. (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company)** is pleased to announce updates to its Board of Directors. Ashleigh Vogstad is stepping down from the Board, and Vanni Barbon has been appointed as a Director and the new Audit Chair.

Mr. Barbon's professional experience is extensive; as a BMO Commercial Branch Manager, Investment Analyst, and a public company Chief Financial Officer. “We are thrilled to welcome Vanni to the Company, as his banking and public market expertise will be a tremendous asset to the team,” commented Meris Kott, Xtacy, CEO.

“On behalf of the Board and management, I would like to thank Ashleigh for her exceptional service and contributions to the Company. We look forward to her continued advice when possible,” added Kott.

**About Xtacy Therapeutics Corp. :**

Xtacy is a prospect generator that provides high-growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

**For further information visit website:**

[www.xtacytherapeutics.com](http://www.xtacytherapeutics.com)

Or Contact Meris Kott CEO email to [info@xtacytherapeutics.com](mailto:info@xtacytherapeutics.com) (604) 484-0355

Further information about the Company is available on [www.SEDARplus.com](http://www.SEDARplus.com) under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.